ASX: EIQ **16 November 2026**

Healthcare executive and former senior FDA official Dr Vasum Peiris appointed as Chief Medical Officer

- **Dr Vasum Peiris appointed Executive Vice President and Chief Medical Officer, bringing nearly two decades of senior leadership across healthcare, with experience spanning cardiovascular medicine, medical technology, regulatory policy and academia**
- **Served for a decade as Chief Medical Officer and Associate Director for Pediatrics and Special Populations at the US Food and Drug Administration's Center for Devices and Radiological Health**
- **Led strategic and policy initiatives spanning digital health, AI and real-world evidence, advancing approaches to clinical evidence generation and medical technology development and innovation**
- **Led cardiovascular care, research and medical education at a US academic medical center, where he served as Chief of Pediatric and Adult Congenital Cardiology and held an endowed chair**
- **Appointment strengthens Echo IQ's medical leadership as the Company expands US adoption of EchoSolv AS and advances its regulatory strategy for EchoSolv HF**
- **Dr Peiris will lead EIQ's global medical strategy and partnerships with health systems. He will guide product development, regulatory strategy and clinical evidence generation to support adoption, reimbursement and patient access to the Company's AI-powered technologies**

Sydney, Australia — Echo IQ Limited ("Echo IQ" or "the Company") (ASX: EIQ), a medical technology company developing AI-powered software for cardiovascular care, is pleased to advise it has appointed Dr Vasum Peiris, MD, MPH, as Executive Vice President and Chief Medical Officer (CMO), effective 20 January 2027.

Dr Peiris, a pediatric and adult congenital cardiologist, brings nearly two decades of senior leadership experience across US healthcare, academic medicine and medical technology regulation. He served as Chief Medical Officer and Associate Director for Pediatrics and Special Populations at the US Food and Drug Administration's (FDA) Center for Devices and Radiological Health. Recruited to the FDA through a national search, he spent a decade providing executive, clinical and scientific leadership across medical device policy, regulatory science and national and international programs to advance innovation and patient access.

His appointment comes as Echo IQ expands US adoption of its FDA-cleared EchoSolv AS technology, advances its regulatory strategy for EchoSolv HF and develops additional applications for the EchoSolv platform.

Dr Peiris will report directly to CEO, Mr Dustin Haines and serve on the executive leadership team. He will lead Echo IQ's global medical strategy and its partnerships with health systems. He will guide the development of clinical evidence across the EchoSolv portfolio, inform product development and regulatory strategy, and advise the Board on medical and scientific matters. He will also work with the Company's clinical and commercial teams to support adoption, reimbursement and patient access across markets.

At the FDA, Dr Peiris set strategic direction for initiatives to strengthen the clinical evidence used to evaluate new medical technologies. Working with colleagues across the agency, he helped shape how the FDA evaluates digital health technologies, including AI-enabled medical devices, and how it uses real-world evidence to assess device performance across patient populations and care settings.

Dr Peiris worked with leaders across the US Department of Health and Human Services (HHS) to develop national programs addressing barriers to medical device development and patient access. He led collaborations with academic institutions, industry, professional societies and patient communities. A priority

was to bring clinical, regulatory and payer perspectives into studies at the design stage, when the choice of patients and outcomes determines which questions a study can answer about clinical care, regulatory review and coverage.

Before joining the FDA, Dr Peiris served as Chief of Pediatric and Adult Congenital Cardiology at Texas Tech University Health Sciences Center and University Medical Center, and held the Joon Park, MD, Endowed Chair in Medical Excellence. He led multidisciplinary teams in complex cardiovascular care and research, and his educational work spanned medicine, law, and public health. He held academic appointments in the departments of Pediatrics and Internal Medicine, and in the Graduate School of Biomedical Sciences.

Dr Peiris provides clinical service at Children's National Hospital, with a focus on advanced cardiovascular imaging for pediatric and adult patients with congenital heart disease. He holds an academic appointment as Professor (adjunct) at the George Washington University School of Medicine and Health Sciences. He is board-certified by both the American Board of Internal Medicine and the American Board of Pediatrics, and is a Fellow of the American College of Cardiology, the American Society of Echocardiography and the American Academy of Pediatrics.

Dr Peiris is also an accomplished research scientist and author who has delivered invited keynote addresses to academic, scientific and professional audiences internationally. His board service includes the Advisory Board of the American Board of Artificial Intelligence in Medicine. His collaborative, cross-cutting, and innovative leadership has been recognised with 18 FDA awards, including the Commissioner's Award of Excellence and the Commissioner's Special Citation. In 2026, the American Academy of Pediatrics recognised him with its Award for Innovation.

Dr Peiris earned his undergraduate degree at Yale University and graduate degree from the Yale School of Medicine's Department of Epidemiology and Public Health. He earned his medical degree at the University of Vermont College of Medicine, where he received an Alpha Omega Alpha Honor Medical Society scholarship and was selected as an Albert Schweitzer Fellow. He completed residency at the Yale School of Medicine and Yale–New Haven Hospital. He completed fellowship in congenital cardiology and cardiovascular research at Harvard Medical School and Boston Children's Hospital. He pursued further training in advanced cardiovascular imaging at Boston Children's Hospital and Beth Israel Deaconess Medical Center.

Management Commentary:

CEO, Mr Dustin Haines, said: *"Vasum's appointment is a significant addition to our US leadership team and brings an exceptional combination of cardiovascular expertise, senior FDA experience and a deep understanding of the clinical and regulatory requirements for bringing innovative medical technologies into mainstream healthcare.*

Having spent a decade in senior leadership at the FDA, Vasum brings valuable insight into medical device regulation, clinical evidence requirements and the broader US healthcare environment. His experience is highly relevant to Echo IQ as we continue progressing our regulatory strategy for EchoSolv HF, while accelerating commercial adoption of EchoSolv AS.

Importantly, his appointment also supports our longer-term strategy of establishing EchoSolv as a leading multi-condition cardiovascular AI platform. As we expand our clinical partnerships, commercial footprint and product pipeline, Vasum's expertise will support our efforts to translate our technology into broader clinical adoption and commercial growth."

Incoming Executive VP and Chief Medical Officer, Dr Vasum Peiris, said: *"Echo IQ has developed an innovative technology platform with the potential to meaningfully improve how cardiovascular disease is identified and managed. The opportunity to apply artificial intelligence to routinely acquired cardiac imaging*

data represents an important advancement in supporting clinical decision-making, with the goal of improving patient outcomes.

I am excited to join the Company at this stage of its development and work alongside the leadership team to advance its clinical and regulatory programs, strengthen engagement with healthcare providers and support the broader adoption of EchoSolv across the US healthcare system.

My focus will be on ensuring that Echo IQ's technology development and commercial expansion are supported by robust clinical evidence, clear regulatory strategies and meaningful integration into clinical practice."

- ENDS -

Authorised for release by the Board of Directors of Echo IQ Limited.

Investor Enquiries:
Andrew Grover, Executive Chair
Andrew.grover@echoiq.ai / investor@echoiq.ai

Henry Jordan, Six Degrees Investor Relations
Henry.jordan@sdir.com.au / +61 (0) 431 271 538

ABOUT ECHO IQ
Echo IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology. The company is based in Sydney, Australia.

FORWARD-LOOKING STATEMENTS
This announcement contains forward-looking statements, including statements about Echo IQ's commercial, product development and regulatory plans for the EchoSolv platform. These statements reflect the Company's current expectations and are subject to risks and uncertainties, many of which are outside the Company's control, including the outcome of regulatory reviews. Actual results may differ materially from those expressed or implied. Except as required by law or the ASX Listing Rules, Echo IQ does not undertake to update any forward-looking statement.